# A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

> **NCT03895203** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 852 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Bimekizumab
- **DRUG:** Adalimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03895203
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-03
- **Primary completion:** 2021-08-17
- **Final completion:** 2022-07-11
- **Target enrollment:** 852 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895203, "A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03895203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*